BRPI0410340A - vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas - Google Patents

vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas

Info

Publication number
BRPI0410340A
BRPI0410340A BRPI0410340-8A BRPI0410340A BRPI0410340A BR PI0410340 A BRPI0410340 A BR PI0410340A BR PI0410340 A BRPI0410340 A BR PI0410340A BR PI0410340 A BRPI0410340 A BR PI0410340A
Authority
BR
Brazil
Prior art keywords
vectors
cells
derived
transgenic plant
preparing
Prior art date
Application number
BRPI0410340-8A
Other languages
English (en)
Inventor
Guy A Cardineau
Hugh Stanley Mason
Joyce M Vaneck
Dwayne D Kirk
Amanda Maree Walmsley
Original Assignee
Dow Agrosciences Llc
Thompson Boyce Plant Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc, Thompson Boyce Plant Res filed Critical Dow Agrosciences Llc
Publication of BRPI0410340A publication Critical patent/BRPI0410340A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"VETORES E CéLULAS PARA PREPARAR COMPOSIçõES IMUNOPROTETORAS DERIVADAS DE PLANTAS TRANSGêNICAS". A invenção é dirigida aos vetores e aos métodos úteis para preparar células de plantas geneticamente transformadas, que expressam imunógenos de organismos patogênicos que são usados para produzir partículas imunoprotetoras úteis em preparações de vacinas. A invenção inclui os genes otimizados em plantas que codificam a proteína HN do Vírus da Doença de Newcastle. A invenção também se relaciona aos métodos de produzir um antígeno em uma planta transgênica.
BRPI0410340-8A 2003-05-05 2004-05-04 vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas BRPI0410340A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46799803P 2003-05-05 2003-05-05
PCT/US2004/014182 WO2004098533A2 (en) 2003-05-05 2004-05-04 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants

Publications (1)

Publication Number Publication Date
BRPI0410340A true BRPI0410340A (pt) 2006-05-30

Family

ID=33435152

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410340-8A BRPI0410340A (pt) 2003-05-05 2004-05-04 vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas

Country Status (13)

Country Link
US (3) US7132291B2 (pt)
EP (1) EP1620550B1 (pt)
KR (1) KR20060035596A (pt)
CN (1) CN100393870C (pt)
AR (1) AR044246A1 (pt)
AT (1) ATE473271T1 (pt)
AU (1) AU2004235813B2 (pt)
BR (1) BRPI0410340A (pt)
CA (1) CA2524293A1 (pt)
DE (1) DE602004028004D1 (pt)
NZ (1) NZ543348A (pt)
WO (1) WO2004098533A2 (pt)
ZA (1) ZA200508930B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
CN1326998C (zh) * 2004-11-25 2007-07-18 中国农业科学院哈尔滨兽医研究所 编码h5亚型禽流感病毒血凝素蛋白的基因及其应用
JP2009502207A (ja) 2005-08-03 2009-01-29 フラウンホーファー ユーエスエー， インコーポレイテッド イムノグロブリンの産生のための組成物および方法
AU2006312126A1 (en) * 2005-11-04 2007-05-18 Dow Agrosciences Llc Preparation of vaccine master cell lines using recombinant plant suspension cultures
KR20080106434A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Ｈｐｖ 항원, 백신 조성물 및 관련된 방법
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
BRPI0707733B1 (pt) * 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
AR060565A1 (es) * 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
KR100766775B1 (ko) * 2006-04-24 2007-11-01 대한민국 장출혈성대장균(ｅｈｅｃ) 감염증 예방용 톡소이드 백신
CN100487119C (zh) * 2006-05-09 2009-05-13 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒H5亚型HA蛋白的重组新城疫LaSota弱毒疫苗株
AU2007261196A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US20080241188A1 (en) * 2007-03-30 2008-10-02 Zeon Corporation Turkey herpesvirus vectored recombinant containing avian influenza genes
EP2152301A4 (en) * 2007-04-28 2010-07-28 Fraunhofer Usa Inc TRYPANOSOMAANTIGEN, VACCINE COMPOSITIONS AND RELATED METHODS
DK2155880T3 (en) * 2007-06-15 2016-12-05 Medicago Inc Modification of glycoproteinproduktion i plants
KR100964462B1 (ko) * 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009076778A1 (en) * 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009026397A2 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
AU2009267769B2 (en) 2008-07-08 2015-07-16 Medicago Inc. Soluble recombinant influenza antigens
NZ590351A (en) 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
KR101773431B1 (ko) * 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
EP2519636B8 (en) 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CA2816190C (en) 2010-10-27 2020-03-24 Philip Morris Products S.A. Methods for capturing virus like particles from plants using expanded bed chromatography
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
NZ622731A (en) * 2011-09-30 2016-04-29 Medicago Inc Increasing virus-like particle yield in plants
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
ES2803508T3 (es) 2013-03-28 2021-01-27 Medicago Inc Producción de partículas similares al virus de la gripe en plantas
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
RU2699982C2 (ru) 2014-01-10 2019-09-11 Медикаго Инк. Энхансерные элементы cpmv
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN117999352A (zh) * 2021-08-24 2024-05-07 富优基尼以色列股份有限公司 用于植物细胞的序列和启动子以及制备和使用此类序列的方法
WO2023237726A1 (en) * 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339307C (en) * 1988-09-06 1997-08-19 Roy Curtiss, Iii Oral immunization by transgenic plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US20010053367A1 (en) * 1991-08-26 2001-12-20 Prodigene, Inc. Vaccines expressed in plants
US6034298A (en) * 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5426108A (en) * 1993-11-10 1995-06-20 American Cyanamid Company Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2
MX9703017A (es) * 1994-10-24 1997-10-31 Texas A & M Univ Sys Inmunizacion oral con plantas transgenicas.
DK0770397T3 (da) * 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
US6395964B1 (en) * 1995-10-24 2002-05-28 The Texas A&M University System Oral immunization with transgenic plants
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
CA2441699A1 (en) * 2001-04-13 2002-10-24 Boyce Thompson Institute For Plant Research Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives

Also Published As

Publication number Publication date
AU2004235813A1 (en) 2004-11-18
EP1620550A2 (en) 2006-02-01
WO2004098533A2 (en) 2004-11-18
US7132291B2 (en) 2006-11-07
US20090017065A1 (en) 2009-01-15
CN100393870C (zh) 2008-06-11
NZ543348A (en) 2008-08-29
US20050048074A1 (en) 2005-03-03
DE602004028004D1 (de) 2010-08-19
EP1620550B1 (en) 2010-07-07
ZA200508930B (en) 2007-03-28
ATE473271T1 (de) 2010-07-15
AU2004235813B2 (en) 2010-07-29
US7407802B2 (en) 2008-08-05
AR044246A1 (es) 2005-09-07
WO2004098533A3 (en) 2005-08-04
US20080076177A1 (en) 2008-03-27
EP1620550A4 (en) 2006-06-14
CN1788077A (zh) 2006-06-14
CA2524293A1 (en) 2004-11-18
KR20060035596A (ko) 2006-04-26

Similar Documents

Publication Publication Date Title
BRPI0410340A (pt) vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas
WO2009076778A8 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
MY161965A (en) New influenza virus immunizing epitope
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
DE69533964D1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
BR0109118A (pt) Métodos para produzir plantas tolerantes a glifosato e composições disso
BRPI0710689A2 (pt) método para preparação de uma vacina de aiv feita de planta e a referida vacina
SI2635257T1 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
WO2009082664A3 (en) Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
AR082427A2 (es) Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus
BR0307155A (pt) plantas transgênicas expressando proteìnas modificadas por civps ou inteìnas e método relativo
DK1443960T3 (da) Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme
BR112023019301A2 (pt) Formulações de vacina de coronavírus
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
WO2007053183A3 (en) Chloroplasts engineered to express pharmaceutical proteins
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
Omoniyi et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
BR0212530A (pt) Proteìnas reforçadas e métodos para seu uso
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.